Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2162-3619
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis ; volume:11 ; number:1 ; day:28 ; month:2 ; year:2022 ; pages:1-3 ; date:12.2022
Experimental hematology & oncology ; 11, Heft 1 (28.2.2022), 1-3, 12.2022
- Creator
-
Hunter, Bradley D.
Hoda, Daanish
Nguyen, Andy
Gouw, Launce
Huber, Bryan
Jensen, Ryan R.
Preedit, Justine
Evens, Andrew
Huang, Esther
Park, Jiyeon
Cooper, Dennis L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-022-00266-1
- URN
-
urn:nbn:de:101:1-2022052819332195518263
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hunter, Bradley D.
- Hoda, Daanish
- Nguyen, Andy
- Gouw, Launce
- Huber, Bryan
- Jensen, Ryan R.
- Preedit, Justine
- Evens, Andrew
- Huang, Esther
- Park, Jiyeon
- Cooper, Dennis L.
- SpringerLink (Online service)
Other Objects (12)
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
Chimeric Antigen Receptor T-Cell Therapy
Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
Chimeric antigen receptor T‑cell therapy—a hematological success story
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
The 4-1BBζ costimulatory domain in chimeric antigen receptors enhances CD8+ T-cell functionality following T-cell receptor stimulation
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
Chimeric Antigen Receptor T-Cell Therapy
Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
Chimeric antigen receptor T‑cell therapy—a hematological success story
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
The 4-1BBζ costimulatory domain in chimeric antigen receptors enhances CD8+ T-cell functionality following T-cell receptor stimulation
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis
Chimeric Antigen Receptor T-Cell Therapy
Sacituzumab-govitecan-induced severe acute tubulointerstitial nephritis requiring hemodialysis
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
Chimeric antigen receptor T‑cell therapy—a hematological success story
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Chimeric antigen receptor T-cell therapy for relapsed and refractory thyroid cancer
A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma
The 4-1BBζ costimulatory domain in chimeric antigen receptors enhances CD8+ T-cell functionality following T-cell receptor stimulation
Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies